Washington DC  is about to get a new Cancer Center and one of the biggest names in personalised medicine

Eduardo Sotomayor, M.D., is moving from Moffit Cancer Center’s personalised medicine program to head up the new George Washington Cancer Center (GWCC). The new center is a collaborative effort between George Washington (GW) School of Medicine and Health Sciences, George Washington University Hospital, and George Washington Medical Faculty Associates. As the inaugural director, Sotomayor, will be looking to establish the GWCC as the premier cancer center for Washington, D.C., and attain the NCI’s designation within the decade.

“GW is making an historic commitment to advance basic science and translational discoveries in cancer, while providing cancer patients with greater opportunities for cutting-edge treatments and enhancing our efforts in cancer prevention,” said Jeffrey S. Akman, M.D., vice president for health affairs at GW, Walter A. Bloedorn Professor of Administrative Medicine, and dean of the GW SMHS. “In 2016, with oversight by Dr. Sotomayor, GW SMHS will open a cancer research center in the new GW Science and Engineering Hall. Located in the largest academic facility in the nation’s capital dedicated to science and engineering research and education, this unparalleled setting will provide extraordinary opportunities for cross-disciplinary collaboration and innovative partnerships across the university.”

In addition to leading the GW Cancer Center, Sotomayor will also join the Department of Medicine’s faculty to serve as a professor of medicine.

“I am humbled and thrilled with my selection as the inaugural director of the GW Cancer Center during this era of transformational changes in the history of GW,” said Sotomayor. “What attracted me the most to GW is the unique opportunity to create a dynamic and innovative cancer center that, because of its location in the nation’s capital, can influence cancer research innovation, as well as cancer policy. This unique platform, together with the strong commitment and investment from the senior leaders of the GW SMHS, the GW Hospital, and the GW Medical Faculty Associates, is clearly a recipe for success.”

As well as directing the GWCC’s research goals, one of Sotomayor’s priorities is to lead in delivery of personalised medicine at point of care. Included in this, is a plan to have the GWCC join the Oncology Research Information Exchange Network. 

“I am proud to welcome Dr. Sotomayor as a member of the Department of Medicine who will advance the clinical, educational, and research mission of the department,” said Alan Wasserman, M.D., chair of the Department of Medicine and president of the GW Medical Faculty Associates. “In joining the largest department in the GW School of Medicine and Health Sciences, he will lead our outstanding faculty in enriching the lives of cancer patients and the community we serve, and I couldn’t be more excited to have someone with Dr. Sotomayor’s reputation and talent lead us in becoming the premiere center for cancer research and patient care.”

It is not only transformative years at GW, but across modern healthcare. There’s an opportunity to spend money wisely and establish new reputations. By targeting personalised medicine, with the opening of a new center under exciting leadership, GW are making it very clear that they intend to be at the top of the class.